{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:45:12Z","timestamp":1773110712737,"version":"3.50.1"},"reference-count":67,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atrial fibrillation is the most common cardiac arrhythmia and conveys a significant risk of morbidity and mortality due to related stroke and systemic embolism. Oral anticoagulation (OAC) is the mainstay of thromboembolism prevention, and management of anticoagulation can be challenging. For patients without significant valvular disease, decisions around anticoagulation therapy are first based on the presence of additional stroke risk factors, as measured by the CHA2DS2-VASc (congestive heart failure, hypertension, age \u226575, diabetes, prior stroke or transient ischemic attack, vascular disease, age 65\u201374, and sex category [female]) score. Patients with increased CHA2DS2-VASc scores (by regional guidelines) should next be evaluated to determine if they are candidates for non\u2013vitamin K antagonist oral anticoagulant (NOAC) therapy. This should focus on assessment of concomitant valve disease and\/or impaired renal function. In eligible patients, the cumulative data support a preference for NOACs over warfarin, as NOACs appear safer and more effective as a group. However, there are no direct, randomized comparisons between NOACs, and therefore, selecting among them can be difficult. In addition, important patient groups remain underrepresented in major clinical trials, and their management is often left to clinician judgment. Data from emerging clinical trials will help guide physicians; however, patient engagement in decisions regarding OAC management will remain vital to ensuring appropriate balance of risks and optimizing health outcomes.<\/jats:p>","DOI":"10.1182\/blood-2016-07-693614","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:10:04Z","timestamp":1477440604000},"page":"2891-2898","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["How I use anticoagulation in atrial fibrillation"],"prefix":"10.1182","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4729-7820","authenticated-orcid":false,"given":"Benjamin A.","family":"Steinberg","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Utah Health Sciences Center, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"18","key":"2019111903063542900_B1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"2019111903063542900_B2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.28.10.973","article-title":"Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study","volume":"28","author":"Wolf","year":"1978","journal-title":"Neurology"},{"issue":"9","key":"2019111903063542900_B3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study","volume":"147","author":"Wolf","year":"1987","journal-title":"Arch Intern Med"},{"issue":"1","key":"2019111903063542900_B4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2009","article-title":"Pathophysiological mechanisms of atrial fibrillation: a translational appraisal [published correction appears in Physiol Rev. 2011;91(4):1533]","volume":"91","author":"Schotten","year":"2011","journal-title":"Physiol Rev"},{"issue":"3","key":"2019111903063542900_B5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/STROKEAHA.115.012004","article-title":"Atrial fibrillation and mechanisms of stroke: time for a new model","volume":"47","author":"Kamel","year":"2016","journal-title":"Stroke"},{"issue":"7","key":"2019111903063542900_B6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"issue":"23","key":"2019111903063542900_B7","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society [published correction appears in Circulation. 2014;130(23):e272-e274]","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"issue":"21","key":"2019111903063542900_B8","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"13","key":"2019111903063542900_B9","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903063542900_B10","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/europace\/euu178","article-title":"The definition of valvular and non-valvular atrial fibrillation: results of a physicians\u2019 survey","volume":"16","author":"Molteni","year":"2014","journal-title":"Europace"},{"issue":"47","key":"2019111903063542900_B11","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u2018valvular\u2019 atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"issue":"22","key":"2019111903063542900_B12","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"2019111903063542900_B13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2019111903063542900_B14","first-page":"ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO) [published online ahead of print 27 August 2016]","volume":"2016","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"2019111903063542900_B15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2019111903063542900_B16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"46","key":"2019111903063542900_B17","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O\u2019Brien","year":"2015","journal-title":"Eur Heart J"},{"issue":"19","key":"2019111903063542900_B18","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"2019111903063542900_B19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","article-title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry","volume":"128","author":"Steinberg","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"2019111903063542900_B20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111903063542900_B21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111903063542900_B22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111903063542900_B23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"9921","key":"2019111903063542900_B24","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2019111903063542900_B25","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation.V2012.1.536.3798545","article-title":"New oral anticoagulants: which one should my patient use?","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Weitz","year":"2012"},{"issue":"1","key":"2019111903063542900_B26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/clc.22204","article-title":"Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation","volume":"37","author":"Savelieva","year":"2014","journal-title":"Clin Cardiol"},{"key":"2019111903063542900_B27","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2 [published online ahead of print 4 February 2016]","author":"Diener","journal-title":"Eur Heart J"},{"key":"2019111903063542900_B28","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. [published online ahead of print 4 February 2016]","author":"Diener","journal-title":"Eur Heart J"},{"issue":"5","key":"2019111903063542900_B29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"issue":"9","key":"2019111903063542900_B30","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111903063542900_B31","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jacc.2015.09.024","article-title":"Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF Trial","volume":"66","author":"Sherwood","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2019111903063542900_B32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111903063542900_B33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.116.021831","article-title":"Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents","volume":"134","author":"Ruff","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"2019111903063542900_B34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/hrt.2004.042465","article-title":"Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population","volume":"91","author":"Jones","year":"2005","journal-title":"Heart"},{"issue":"3","key":"2019111903063542900_B35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"issue":"6","key":"2019111903063542900_B36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","article-title":"Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)","volume":"61","author":"Patel","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2019111903063542900_B37","doi-asserted-by":"crossref","first-page":"e000521","DOI":"10.1161\/JAHA.113.000521","article-title":"Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial","volume":"3","author":"Piccini","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"2019111903063542900_B38","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","article-title":"Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation","volume":"127","author":"Wallentin","year":"2013","journal-title":"Circulation"},{"issue":"2 suppl","key":"2019111903063542900_B39","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"suppl 1","key":"2019111903063542900_B40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ijlh.12537","article-title":"Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin","volume":"38","author":"Onundarson","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"9526","key":"2019111903063542900_B41","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"issue":"20","key":"2019111903063542900_B42","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903063542900_B43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7326\/0003-4819-155-9-201111010-00004","article-title":"Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable","volume":"155","author":"Connolly","year":"2011","journal-title":"Ann Intern Med"},{"issue":"12","key":"2019111903063542900_B44","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jacc.2015.08.002","article-title":"Bridging anticoagulation: primum non nocere","volume":"66","author":"Rechenmacher","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2019111903063542900_B45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCULATIONAHA.114.011777","article-title":"Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"131","author":"Steinberg","year":"2015","journal-title":"Circulation"},{"issue":"9","key":"2019111903063542900_B46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"issue":"2 suppl","key":"2019111903063542900_B47","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"issue":"47","key":"2019111903063542900_B48","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"2019111903063542900_B49","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2019111903063542900_B50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"issue":"21","key":"2019111903063542900_B51","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","article-title":"Temporal relationship between subclinical atrial fibrillation and embolic events","volume":"129","author":"Brambatti","year":"2014","journal-title":"Circulation"},{"issue":"9","key":"2019111903063542900_B52","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.hrthm.2011.04.022","article-title":"Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS","volume":"8","author":"Daoud","year":"2011","journal-title":"Heart Rhythm"},{"issue":"45","key":"2019111903063542900_B53","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"issue":"9872","key":"2019111903063542900_B54","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"2019111903063542900_B55","doi-asserted-by":"crossref","first-page":"e002587","DOI":"10.1161\/JAHA.115.002587","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial","volume":"5","author":"Xu","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2019111903063542900_B56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"issue":"20","key":"2019111903063542900_B57","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111903063542900_B58","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111903063542900_B59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903063542900_B60","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jacc.2014.06.1193","article-title":"Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review","volume":"64","author":"Dewilde","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2019111903063542900_B61","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","article-title":"An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)","volume":"169","author":"Gibson","year":"2015","journal-title":"Am Heart J"},{"issue":"16","key":"2019111903063542900_B62","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.115.019794","article-title":"Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage","volume":"133","author":"Chao","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"2019111903063542900_B63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","article-title":"Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry","volume":"123","author":"Reddy","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"2019111903063542900_B64","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","article-title":"Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial","volume":"127","author":"Reddy","year":"2013","journal-title":"Circulation"},{"issue":"9689","key":"2019111903063542900_B65","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"2019111903063542900_B66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2019111903063542900_B67","doi-asserted-by":"crossref","first-page":"g2116","DOI":"10.1136\/bmj.g2116","article-title":"Anticoagulation in atrial fibrillation","volume":"348","author":"Steinberg","year":"2014","journal-title":"BMJ"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/25\/2891\/1396911\/blood693614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/25\/2891\/1396911\/blood693614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:07:00Z","timestamp":1574132820000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/25\/2891\/35667\/How-I-use-anticoagulation-in-atrial-fibrillation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,22]]},"references-count":67,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2016,12,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-07-693614","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,22]]}}}